US acquisition of Rosemont Pharmaceuticals
US-based Bio-Technology General Corporation (BTG) has completed its £61m (US$94m) purchase of Rosemont Pharmaceuticals, based in Leeds in the UK. Rosemont is a subsidiary of Akzo Nobel and a leader in the UK market for oral liquid formulations of branded non-proprietary drugs. The acquisition provides BTG with a valuable presence in the European specialty pharmaceutical marketplace, according to Sim Fass, BTG chairman and ceo.
Products manufactured and marketed by Rosemont include CNS and cardiovascular drugs and a recently introduced patented oral liquid formulation of tamoxifen, trademarked Soltamox, for the treatment of breast cancers. Global rights to the tamoxifen product are also included in the acquisition.